169 results about "Hematological malignancy" patented technology

The present invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating cancer (e.g., hematological malignancies in humans). A variety of biomarker chromosomal number alterations (CNAs) and biomarkers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the biomarker CNAs and / or alterations in the amount, structure, and / or activity of one or more of the biomarkers comprised within the CNAs is associated with cancer status.

A compound of formula 1 and / or its salts, tautomers or solvates is used to treat hematological malignancies. In an embodiment, an organic acid salt of compound 1 is provided for general use in treatment of neoplasms, and in a further embodiment the salt is stabilized with carbohydrate.

A method for diagnosis of a hematological malignancy of a subject is provided. The method comprises obtaining a second derivative of an infrared (IR) spectrum of a population of mononuclear cells by analyzing the population of mononuclear cells by infrared spectroscopy, and based on the second derivative of the infrared spectrum, generating an output indicative of the presence of a hematological malignancy. Other applications are also described.

Disclosed are methods and compositions for the detection, diagnosis, prognosis, and therapy of hematological malignancies, and in particular, B cell leukemias, lymphomas and multiple myelomas. Disclosed are compositions, methods and kits for eliciting immune and T cell responses to specific malignancy-related antigenic polypeptides and antigenic polypeptide fragments thereof in an animal. Also disclosed are compositions and methods for use in the identification of cells and biological samples containing one or more hematological malignancy-related compositions, and methods for the detection and diagnosis of such diseases and affected cell types. Also disclosed are diagnostic and therapeutic kits, as well as methods for the diagnosis, therapy and / or prevention of a variety of leukemias and lymphomas.

Provided are methods for clinical treatment of hematological malignancies, such as relapsed or refractory chronic lymphocytic leukemia or lymphoma using an anti-LAG-3 antibody. Particular malignancies include, e.g., chronic lymphocytic leukemia (CLL), Hodgkin lymphoma (HL), or non-Hodgkin lymphoma (NHL).

Provided are combination therapies comprising an anti-CD38 antibody and cyclophosphamide for CD38-positive hematological malignancies.

Use of a chimeric protein selected from the group consisting of CTLA4-FasL and CD40-FasL proteins for treatment of lymphoma and / or a multiple myeloma and / or a leukemia as described herein, and pharmaceutical compositions and methods of treatment thereof.

A method for treating patients afflicted with cancer (including hematological malignancies) or viral infections, wherein the patients are under treatment or are to be treated with at least one anticancer or antiviral agent, and in particular (deoxy)nucleotide or (deoxy)nucleoside analog drugs, includes administering at least one small molecule inhibitor / activator (including ATP competitive inhibitors, signal transduction inhibitors / activators, protein kinase inhibitors / activators, and tyrosine kinase inhibitors / activators) in combination with the (deoxy) nucleotide or (deoxy)nucleoside analog, and wherein the small molecule inhibitor / activator is administered in sufficient amount to modulate deoxynucleotide or deoxynucleoside kinase activity (and in particular deoxycytidine kinase activity) to modulate activation of the (deoxy)nucleotide or (deoxy)nucleoside analog in vivo with a subsequent therapeutically beneficial anticancer or antiviral effect. The combined treatments together include a therapeutically effective amount.

The present invention relates to methods for the treatment of hematological malignancies. In particular, the invention provides methods for treatment of hematological malignancies by administering Aurora kinase inhibitors in combination with anti-CD20 antibodies.

Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.

Disclosed are methods and compositions for the detection, diagnosis, prognosis, and therapy of hematological malignancies, and in particular, B cell leukemias, lymphomas and multiple myelomas. Disclosed are compositions, methods and kits for eliciting immune and T cell responses to specific malignancy-related antigenic polypeptides and antigenic polypeptide fragments thereof in an animal. Also disclosed are compositions and methods for use in the identification of cells and biological samples containing one or more hematological malignancy-related compositions, and methods for the detection and diagnosis of such diseases and affected cell types. Also disclosed are diagnostic and therapeutic kits, as well as methods for the diagnosis, therapy and / or prevention of variety of leukemias and lymphomas.

The invention discloses a method for promoting cell proliferation and activation of peripheral blood CD4+T lymphocyte and suppressing cell proliferation and migration of acute lymphocytic leukemia (ALL) Jurkat T cells by using red cassia tree lectin. The separation and purification of red cassia tree lectin from red cassia tree seeds can be carried out at the temperature of 1-5 DEG C during the entire process, the proliferation and activation of the peripheral blood T lymphocyte CD4 subgroup can be promoted by the red cassia tree lectin through the verifications of an MTT (3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide) experiment, a DNA (deoxyribonucleic acid) analysis and an FCM (flow cytometry), and the red cassia tree lectin is CD4+T lymphocyte mitogen more efficient than PHA (Phytohaemagglutinin) and provides a new and effective way for anti-virus infection and vaccine intensifier development; through the verifications of CCK-8 (Cell Counting Kit-8) experiment, DNA analysis, cell apoptosis analysis, ELISA (enzyme-linked immuno sorbent assay) experiments and migration assay, the red cassia tree lectin can obviously suppress the proliferation and migration of the Jurkat T lymphocyte, is a growth inhibitor more efficient for the ALL cells and provides a new and effective supplementary means for treating the hematological malignancies.

The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of a variety of hematological malignancies, including acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). The present invention also provides methods for making the oral arsenic trioxide formulation. Methods of using the oral arsenic trioxide formulation are also described.

The present invention relates to methods of treatment of light chain amyloidosis and other CD38-positive hematological malignancies with anti-CD38 antibodies.

Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.

Provided herein are methods that relate to a therapeutic strategy for treatment of cancer, including hematological malignancies. In particular, the methods include administration entospletinib and a Bcl-2 inhibitor, such as venetoclax, navitoclax, and ABT-737.